260 related articles for article (PubMed ID: 20586516)
1. Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Arcese A; Aste N; Bettacchi A; Camplone G; Cantoresi F; Caproni M; D'Amico D; Fabbri P; Filosa G; Galluccio A; Hansel K; Lisi P; Micali G; Musumeci ML; Nicolini M; Parodi A; Patania M; Pezza M; Potenza C; Richetta A; Simonacci M; Trevisan P; Valenti G; Calvieri S
Clin Drug Investig; 2010; 30(8):507-16. PubMed ID: 20586516
[TBL] [Abstract][Full Text] [Related]
2. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
4. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
[TBL] [Abstract][Full Text] [Related]
5. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
8. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
9. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
Papp KA; Barber K; Bissonnette R; Bourcier M; Lynde CW; Poulin Y; Shelton J; Toole J; Vieira A; Poulin-Costello M
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):361-366. PubMed ID: 24980988
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
12. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
[TBL] [Abstract][Full Text] [Related]
13. Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.
Esposito M; Giunta A; Mazzotta A; Babino G; Talamonti M; Chimenti MS; Chimenti S
Int J Immunopathol Pharmacol; 2010; 23(2):503-9. PubMed ID: 20646345
[TBL] [Abstract][Full Text] [Related]
14. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
15. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
Weinberg JM
Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
17. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
18. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
19. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
20. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
